Francesco A.
- Country
- Italy
- Department
- Alma Mater Studiorum – University of Bologna, IRCCS Azienda Ospedaliero Universitaria di Bologna
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Efruxifermin in Non-Cirrhotic NASH/MASH with Fibrosis
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Efruxifermin in Compensated Cirrhosis Due to NASH/MASH
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Lanifibranor in Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages F2/F3
Data & Insights
Has run more than one trial at 45 of 131 partner sites.
Specializations
Liver Disease Management
This investigator specializes in treating chronic liver conditions, with particular emphasis on non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). Their research extends to various stages of liver disease, from non-cirrhotic conditions to compensated cirrhosis.
- Advanced Liver Fibrosis Treatment
- NASH/MASH Resolution Strategies
- Liver Disease Progression Management
Cholestatic Liver Diseases
The investigator focuses on innovative treatments for primary biliary cholangitis (PBC), exploring combination therapies and long-term management approaches. Their work includes evaluation of biochemical disease markers and bile acid homeostasis.
- PBC Treatment Optimization
- Biomarker Analysis
- Long-term Disease Management
Metabolic Liver Disease
Research interests include the intersection of metabolic dysfunction and liver disease, with expertise in treating liver fibrosis across multiple stages. The investigator studies innovative therapeutic approaches for metabolic liver conditions.
- Metabolic Disease Markers
- Fibrosis Assessment
- Clinical Outcome Evaluation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.